Aims and scope
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
EJNMMI Journal Family
Discover featured content, editor’s highlights, and the latest research via our Gateway to the EJNMMI Journal Family.
EJNMMI Research aims to be a platform of lively scientific exchange on new findings in basic, translational and clinical research in nuclear medicine and related matters. It addresses research in biology and medicine together with radiochemistry, radiopharmacy, radiophysics, dosimetry and instrumentation. The open access model speeds up the publication process and therefore favours rapid communication of new scientific results, even if still preliminary. Manuscripts are accepted for publication only after thorough peer review.
EJNMMI Research has been launched by Springer as a companion journal to the EJNMMI and not as a competitor. It offers space to authors whose manuscripts, despite high quality, cannot be accommodated by the EJNMMI. Consequently, authors of original manuscripts rejected by the EJNMMI are encouraged to submit their work to EJNMMI Research.
The journal also offers the possibility to publish reviews, short communications and selected case reports. Educational papers set out to improve and expand our understanding and knowledge in active research domains. Editorials and letters complete the exchange of views and ideas. We also welcome submission of well-designed studies that did not confirm the initial hypothesis, as we are convinced that they contribute to the advancement of science and should, therefore, be made available to the scientific community.
Check if your institution is a member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
EANM Sponsorship Programme
The EANM Board decided to allocate funds to a dedicated Publication Fee Sponsorship Programme for the entire EJNMMI journal family. Through this programme, the EANM will cover the charges that arise for selected open choice publications in the EJNMMI and open access publications in EJNMMI Research, EJNMMI Physics, EJNMMI Radiopharmacy and Chemistry as well as the European Journal of Hybrid Imaging. Find out more.
2017 Journal Metrics
31 days to first decision for reviewed manuscripts only
29 days to first decision for all manuscripts
68 days from submission to acceptance
16 days from acceptance to publication
163 Altmetric Mentions
- ISSN: 2191-219X
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.